Member Name:		Member ID:	Member DOB:
Drug Name:		Strength:	Directions:
Physician Name:		Physician Phone #:	Specialty:
Physician Fax #:		Pharmacy Name:	Pharmacy Phone:
		Horizon NJ H Zolgensma – Medical N	
1.		ma being used for? or Atrophy (SMA) pecify):	
2.	Is the medication being proor No	escribed by a pediatric neurologist or pe	ediatric geneticist with expertise in the treatment of SMA? Yes
3.	Does the member have bi-	allelic mutations in the survival motor r	neuron 1 (SMN1) gene? <u>Provide documentation</u> . Yes or No
4.	Will the member's liver fu or No	nction be assessed prior to administration	on of Zolgensma and for at least 3 months after infusion? Yes
5.	Will the member be receive Zolgensma? Yes or No	ing other surviving motor neuron (SMN	N) modifying therapy (e.g., Spinraza®) together with
6.	Does the member have ad-	vanced SMA (e.g., complete paralysis of	f limbs, permanent ventilator dependence)? Yes or No
7.	Has baseline anti-adeno-as	sociated virus serotype 9 (anti-AAV9)	antibody testing been done and titers are $\leq 1:50$? Yes or No
8.		ystemic corticosteroid equivalent to ora to receive corticosteroid therapy for at	l prednisolone 1 mg/kg/day at least 1 day prior to Zolgens ma least a total of 30 days ? Yes or No
9.	Has the member previously received Zolgens ma in their lifetime? Yes or No		
10.	What is the member's curr	ent weight?lbs ORkg	

Physician office's signature*______ Print Name______*Form must be completed and signed by physician or licensed representative from the physician's office